Lymphangioleiomyomatosis: a disease involving the lymphatic system.
about
Novel molecular pathways in Gorham disease: implications for treatmentA Total Pleural Covering for Lymphangioleiomyomatosis Prevents Pneumothorax RecurrenceSex-specific lung diseases: effect of oestrogen on cultured cells and in animal modelsUterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis.Lymphatic vascular morphogenesis in development, physiology, and diseaseLymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell StemnessThe new era of the lymphatic system: no longer secondary to the blood vascular systemLymphangioleiomyomatosis - a wolf in sheep's clothing.Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM)The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.Lymphatic endothelial differentiation in pulmonary lymphangioleiomyomatosis cells.NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function declineOncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.Chasing the Lymph: New Clues for the Management of Idiopathic Plastic Bronchitis.Exonic mutations of TSC2/TSC1 are common but not seen in all sporadic pulmonary lymphangioleiomyomatosis.Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.Emerging Roles for VEGF-D in Human Disease.Chyloptysis with chylopericardium, a rare case and mini-review.Chronic sirolimus therapy for lymphangioleiomyomatosis.Emerging biomarkers of lymphangioleiomyomatosis.Successful treatment of a patient with chyluria due to lymphangioleiomyomatosis using sirolimus.Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance.The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis
P2860
Q27005629-E405F9FB-E69A-4F27-BC35-18A53BC670E3Q27321304-8D2C7BC9-E601-416B-8995-69EC1BA32C1FQ27687650-C2F3A433-237C-4152-858F-377A04156270Q30411083-6D865944-EFEB-4536-88B0-8F7CC6019ECAQ35074335-17BF1A03-D215-437C-BF0A-1524F1E3E90EQ35196040-287AC75F-2A95-428F-B047-A68EF6C373B7Q35689467-439A168B-1C44-483B-9A71-26C7E23DA445Q35852994-246EA40D-DA21-448B-82A0-86C0CBD45FEFQ36357766-CFA7341B-D3F3-4B70-95EA-F4CC4A683893Q36636671-76B3D735-2548-4864-AF4D-E87FCCF319DEQ36708521-59F4816E-3100-4DCB-AA10-10F41A9C07C8Q37047634-C81B46E0-FA9E-4072-8732-866FF0B06732Q37316220-3396AED4-011A-46E6-B4C5-D1330A805C39Q37641575-FDFE231C-B376-4FBF-8C89-1DDF1D05F3D4Q38372196-9F81E9EC-9A3B-4232-8BE5-95F1E2F8A9E9Q41631919-1F76F95A-5911-4732-9E11-6E6D6AD6BA92Q42537376-16E99EDE-B8CB-4989-8EB0-20A59EFACB01Q42595723-EC3765C4-4655-4C6F-8770-FE1F7C36AC43Q47233157-262EC454-90A3-43A0-8B1C-EAA2352FB77EQ47548634-17D4EAB5-A8EC-48CC-A2F7-2A29A517FE48Q48008829-F1EA51B4-1E7F-40BA-965E-05FEBBA90A21Q49679457-EBC4EBB3-0DF2-4969-82D8-0F403A06D367Q49783838-6F937C34-B62A-47CE-BB9C-05306D5EC499Q54495902-6844A74C-DBD0-4795-8A8C-4473EFFED1FCQ58782491-C3B613EA-CFBD-4F6C-9AD0-852D9256E53D
P2860
Lymphangioleiomyomatosis: a disease involving the lymphatic system.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lymphangioleiomyomatosis: a disease involving the lymphatic system.
@en
Lymphangioleiomyomatosis: a disease involving the lymphatic system.
@nl
type
label
Lymphangioleiomyomatosis: a disease involving the lymphatic system.
@en
Lymphangioleiomyomatosis: a disease involving the lymphatic system.
@nl
prefLabel
Lymphangioleiomyomatosis: a disease involving the lymphatic system.
@en
Lymphangioleiomyomatosis: a disease involving the lymphatic system.
@nl
P2093
P356
P1476
Lymphangioleiomyomatosis: a disease involving the lymphatic system.
@en
P2093
Keiko Mitani
Kuniaki Seyama
Masatoshi Kurihara
Teruhiko Sato
Toshio Kumasaka
P356
10.1089/LRB.2009.0018
P577
2010-03-01T00:00:00Z